Reply to "Metformin as a booster or obstacle of immunotherapy in patients with non-small cell lung cancer and diabetes mellitus"

Cancer. 2024 Jan;130(2):324. doi: 10.1002/cncr.35134. Epub 2023 Nov 21.

Authors

Yasmin Leshem^{1

2}, Yardenna Dolev¹, Nava Siegelmann-Danieli^{3

4}, Sarah Sharman Moser³, Lior Apter BPharm^{3

5}, Gabriel Chodick^{3

4}, Alla Nikolaevski-Berlin¹, Sivan Shamai¹, Ofer Merimsky¹, Ido Wolf^{1

4}

Affiliations

¹ Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
² Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
³ Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel.
⁴ Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁵ Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

PMID: 37987227
DOI: 10.1002/cncr.35134

No abstract available

Publication types

Letter
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Diabetes Mellitus, Type 2*
Humans
Immunotherapy / adverse effects
Lung Neoplasms* / drug therapy
Metformin* / therapeutic use

Substances

Metformin